Stroke is the leading cause of long-term disability worldwide. When blood flow to the brain is interrupted, neurons die rapidly — but the post-stroke brain also undergoes a recovery phase driven by neuroplasticity. MSC therapy is being investigated as a way to amplify this recovery window by reducing secondary inflammation and promoting neural repair.
The Timing Question
The inflammatory cascade following stroke peaks in the first 72 hours but persists for weeks to months. MSC therapy is not an acute intervention — it is delivered in the subacute or chronic phase (weeks to months post-stroke) when the goal shifts from saving at-risk tissue to maximizing functional recovery.
Mechanisms of MSC Action in Stroke
Neuroprotection
MSCs secrete VEGF, BDNF, and HGF — factors that promote angiogenesis (new blood vessel formation) and neuronal survival in the peri-infarct zone. Animal models consistently show reduced infarct volume and improved functional outcomes when MSCs are administered post-stroke.
Modulation of Neuroinflammation
Post-stroke neuroinflammation — driven by activated microglia and infiltrating peripheral immune cells — significantly worsens outcomes. MSCs suppress this inflammatory response, reducing levels of TNF-alpha, IL-1β, and IL-6 in the post-stroke brain environment.
Neuroplasticity Enhancement
Evidence from both animal models and early human trials suggests MSC administration promotes synaptic remodeling and axonal sprouting in brain regions adjacent to the infarct — effectively helping the brain 'rewire' more efficiently during the critical recovery window.
Clinical Evidence
A 2020 systematic review in Translational Stroke Research found that across 12 clinical trials, MSC-treated stroke patients showed significantly greater improvements in NIHSS (neurological deficit) and mRS (functional outcome) scores compared to control groups. Most benefit was seen in motor function, followed by speech.
Important Caveats
Stroke recovery with MSC therapy is not rapid or guaranteed. Improvement trajectories typically span 3–6 months. Patients who have had stroke more than 2 years prior tend to show more limited response as the neuroplasticity window narrows. Your physician will give you a frank assessment of expected outcomes based on your stroke history, severity, and current deficits.